Considering the PI3K/AKT pathway is one of the main pathways involved in tumorigenesis and being highly mutated in gynecological cancers, many drugs have been developed to target various proteins of this pathway and to increase the efficiency of anti-cancer treatment, partly via the loss of chemoresistance. The gene discussed is PIK3CA; the disease is female reproductive organ cancer.